Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

BACKGROUND: Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Engelmann, Ulrich, Jahn, Sigbert, Leptich, Alexandra, Kern, Raimar, Hassoun, Lina, Thomas, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950609/
https://www.ncbi.nlm.nih.gov/pubmed/27430352
http://dx.doi.org/10.1186/s12883-016-0629-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950609/
https://www.ncbi.nlm.nih.gov/pubmed/27430352
http://dx.doi.org/10.1186/s12883-016-0629-9

Ejemplares similares